258 related articles for article (PubMed ID: 11165549)
1. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism.
Haim N; Lanir N; Hoffman R; Haim A; Tsalik M; Brenner B
Am J Med; 2001 Feb; 110(2):91-6. PubMed ID: 11165549
[TBL] [Abstract][Full Text] [Related]
2. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C).
Glueck CJ; Wang P; Fontaine RN; Tracy T; Sieve-Smith L; Lang JE
Am J Cardiol; 1999 Sep; 84(5):549-54. PubMed ID: 10482153
[TBL] [Abstract][Full Text] [Related]
3. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism.
Rodeghiero F; Tosetto A
Ann Intern Med; 1999 Apr; 130(8):643-50. PubMed ID: 10215560
[TBL] [Abstract][Full Text] [Related]
4. Activated protein C resistance--a major risk factor for thrombosis.
Rosén SB; Sturk A
Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
[TBL] [Abstract][Full Text] [Related]
5. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.
Price DT; Ridker PM
Ann Intern Med; 1997 Nov; 127(10):895-903. PubMed ID: 9382368
[TBL] [Abstract][Full Text] [Related]
6. Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients - results from the Vienna Cancer And Thrombosis Study (CATS).
Pabinger I; Ay C; Dunkler D; Thaler J; Reitter EM; Marosi C; Zielinski C; Mannhalter C
J Thromb Haemost; 2015 Jan; 13(1):17-22. PubMed ID: 25381723
[TBL] [Abstract][Full Text] [Related]
7. The factor V R2 allele: risk of venous thromboembolism, factor V levels and resistance to activated protein C.
Luddington R; Jackson A; Pannerselvam S; Brown K; Baglin T
Thromb Haemost; 2000 Feb; 83(2):204-8. PubMed ID: 10739373
[TBL] [Abstract][Full Text] [Related]
8. The factor V leiden mutation and the risk of venous thromboembolism in gynecologic oncology patients1.
Ravin AJ; Edwards RP; A Krohn M; Kelley JR; Christopherson WA; Roberts JM
Obstet Gynecol; 2002 Dec; 100(6):1285-9. PubMed ID: 12468175
[TBL] [Abstract][Full Text] [Related]
9. [Activated protein C resistance and venous thrombophilia: molecular genetic prevalence study in the German population].
Ehrenforth S; Klinke S; von Depka Prondzinski M; Kreuz W; Ganser A; Scharrer I
Dtsch Med Wochenschr; 1999 Jun; 124(25-26):783-7. PubMed ID: 10414227
[TBL] [Abstract][Full Text] [Related]
10. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.
Emmerich J; Rosendaal FR; Cattaneo M; Margaglione M; De Stefano V; Cumming T; Arruda V; Hillarp A; Reny JL
Thromb Haemost; 2001 Sep; 86(3):809-16. PubMed ID: 11583312
[TBL] [Abstract][Full Text] [Related]
11. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?
Schambeck CM; Schwender S; Haubitz I; Geisen UE; Grossmann RE; Keller F
Thromb Haemost; 1997 Dec; 78(6):1480-3. PubMed ID: 9423798
[TBL] [Abstract][Full Text] [Related]
12. Inherited thrombophilic risk factors and venous thromboembolism: distinct role in peripheral deep venous thrombosis and pulmonary embolism.
Margaglione M; Brancaccio V; De Lucia D; Martinelli I; Ciampa A; Grandone E; Di Minno G
Chest; 2000 Nov; 118(5):1405-11. PubMed ID: 11083693
[TBL] [Abstract][Full Text] [Related]
13. Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Korean patients with deep vein thrombosis.
Kim TW; Kim WK; Lee JH; Kim SB; Kim SW; Suh C; Lee KH; Lee JS; Seo EJ; Chi HS; Kim SH
J Korean Med Sci; 1998 Dec; 13(6):587-90. PubMed ID: 9886165
[TBL] [Abstract][Full Text] [Related]
14. The prevalence of factor V Leiden as a risk factor for venous thromboembolism in the population of North-Western Greece.
Ioannou HV; Mitsis M; Eleftheriou A; Matsagas M; Nousias V; Rigopoulos C; Vartholomatos G; Kappas AM
Int Angiol; 2000 Dec; 19(4):314-8. PubMed ID: 11305729
[TBL] [Abstract][Full Text] [Related]
15. Resistance to activated protein C--frequent etiologic factor for venous thrombosis.
Simkova M; Simko F; Kovacs L
Bratisl Lek Listy; 2001; 102(5):240-7. PubMed ID: 11725376
[TBL] [Abstract][Full Text] [Related]
16. A case control study of deep venous thrombosis in relation to factor V G1691A (Leiden) and A4070G (HR2 Haplotype) polymorphisms.
Bouaziz-Borgi L; Nguyen P; Hezard N; Musharrafieh U; Almawi WY; Mahjoub T
Exp Mol Pathol; 2007 Dec; 83(3):480-3. PubMed ID: 17555744
[TBL] [Abstract][Full Text] [Related]
17. Risk of venous thromboembolism in association with factor V leiden in cancer patients - The EDITH case-control study.
Heraudeau A; Delluc A; Le Henaff M; Lacut K; Leroyer C; Desrues B; Couturaud F; Tromeur C
PLoS One; 2018; 13(5):e0194973. PubMed ID: 29775482
[TBL] [Abstract][Full Text] [Related]
18. Activated protein C resistance and factor V Leiden mutation can be associated with first-as well as second-trimester recurrent pregnancy loss.
Younis JS; Brenner B; Ohel G; Tal J; Lanir N; Ben-Ami M
Am J Reprod Immunol; 2000 Jan; 43(1):31-5. PubMed ID: 10698038
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of "APTT vs RVVT" based activated protein C resistance assay in the diagnosis of Factor V Leiden mutation.
Baig MA
Indian J Pathol Microbiol; 2020; 63(2):247-250. PubMed ID: 32317524
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and association of the factor V Leiden and prothrombin G20210A in healthy subjects and patients with venous thromboembolism.
Coen D; Zadro R; Honović L; Banfić L; Stavljenić Rukavina A
Croat Med J; 2001 Aug; 42(4):488-92. PubMed ID: 11471205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
